Financials
Financial year 2025
Gross margin
€ -1.3 million
▲ 32% vs 2024
Profit
Caution€ -1.8 million
▼ 177% vs 2024
Debts
Low€ 98,832
▼ 94% vs 2024
Fund+ from Leuven, company number BE0629896521, closed financial year 2025 with a result of € -1.8 million after tax. For that financial year Fund+ recorded a gross margin of € -1.3 million and equity of € 124 million. Compared with financial year 2024, the result moved from € 2.3 million to € -1.8 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
What happened at Fund+?
What happened at Fund+ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Luc Debruyne stepped down as director. NBB
- Chris Buyse stepped down as director. NBB
- François Fontaine stepped down as director. NBB
- LGP Advisory BV stepped down as director. NBB
- Dr. Ir. U. Vandeurzen Management Firm NV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.8 million (▼ 177% vs 2024). Source: NBB ↗
- Chris Buyse became a director. NBB
- Luc Debruyne became a director. NBB
In short
From € 21.4 million profit in 2021 to € 1.8 million loss in 2025.
Paid € 111,922 in corporate taxes since 2021.
Best year ever: 2021, with € 21.4 million profit.
Paid out € 21.7 million in dividends to the owners in total.
A new publication or filing at Fund+? We notify you, reason included.
Follow Fund+Need more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 31.2% of ETHERNA IMMUNOTHERAPIES, 22.8% of Confo Therapeutics, 20.2% of Octimet Oncology NV, 20.1% of Novadip Biosciences, 19.9% of Aelin Therapeutics NV and 19.6% of Ona Therapeutics itself.
Directors
According to the 2025 annual accounts
since 2024 · until 2028
Chris Buyse
Director
Also active at: Life Sciences Research Partners, CoBioRes, Bio-Incubator Leuven
since 2024 · until 2028
François Fontaine
Director
since 2020 · until 2028
Director
since 2024 · until 2028
Dr. Ir. U. Vandeurzen Management Firm NV
Director · represented by Urbanus (roepnaam Urbain) Vandeurzen
Also active at: DI LEGNO INTERIORS, DLI Invest, ALDEA CONSTRUCT +10 more
since 2020 · until 2028
Establishments
Establishment units
Physical locations of this company
Groot Begijnhof 60 box 1
3000 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0629.896.521
- VAT number
- BE 0629.896.521
- Registered office
- Groot Begijnhof 60 bus 1, 3000 Leuven
- Names & denominations
- Fund+
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 May 2015
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Activiteiten van geldmarkt- en niet-geldmarktbeleggingsfondsen
Beleggingstrusts en -fondsen en vergelijkbare financiële instellingen